An Avalere analysis examining Medicare Part D plan tier placement of generic prescription drugs has found that sponsors are increasingly placing generic drugs on higher tiers over time. Overall, 57% of generic drugs are not on 2022 Part D generic tiers, with Medicare Part D plans placing generic prescription drugs on generic tiers just 43% of the time, a decrease from 65% in 2016.
Medicare Part D Patients Paying More For Generics
Over Half Of Generic Drugs Are Not On Medicare Part D Generic Tiers This Year, Avelere Finds
The latest AAM-sponsored study from Avalere Health has found that, for the third year in the row, an increasing percentage of generic drugs are being placed on higher-cost non-generic tiers, even as the overall price of generic drugs decreases.
More from Generics
More from Products
• By
Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.
• By
Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.
• By
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.